MS drug safety survey: do patients and doctors know the risks?

NCT ID NCT05301907

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effects, and risks. The goal was to see if educational materials are working, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siponimod (Mayzent)
What this could lead to: If successful, this survey could show that educational materials help patients and doctors use Mayzent more safely, reducing risks like infections or heart issues.
What could go wrong: This is a completed survey, not a treatment trial. It measures knowledge, not health outcomes, so it won't directly improve MS or change how the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative Site

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.